Naphthyzinum (Naphazoline Nitrate)

Naphazoline nitrate is an alpha‑adrenergic agonist. When applied to the nasal mucosa it stimulates alpha receptors on vascular smooth muscle, causing vasoconstriction. This reduces blood flow to the swollen tissue, decreasing edema and opening the airway.

The appropriate dose of Naphthyzinum is determined by a qualified prescriber based on the patient’s age, severity of symptoms, and clinical response. Users should follow the specific instructions provided on the product label or by their healthcare professional.

Safety data for naphazoline nitrate in pregnancy and lactation are limited. It is classified as a category where the risk cannot be ruled out, so pregnant or nursing women should consult their physician before using the product.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Naphthyzinum contains naphazoline nitrate, an imidazoline sympathomimetic, whereas many alternatives such as oxymetazoline belong to the imidazoline class as well. Both provide rapid vasoconstriction, but differences in potency, duration of action and side‑effect profiles may influence clinician choice.

Store Naphthyzinum at temperatures below 25 °C in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and avoid freezing to maintain product stability.

Naphthyzinum is applied intranasally as a spray. The patient should tilt the head slightly forward, insert the nozzle into one nostril, and spray the recommended amount while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks include rebound nasal congestion after prolonged use, severe hypertension, cardiac arrhythmias, and rare allergic reactions such as facial swelling or rash. Users should discontinue the product and seek medical attention if any of these events occur.

Naphthyzinum should be avoided in individuals with uncontrolled hypertension, severe cardiovascular disease, narrow‑angle glaucoma, or known hypersensitivity to naphazoline nitrate. Children under six years of age should not use it without explicit medical guidance.